Friday, October 30, 2026 · Edition updated 6:00 AM ETFRI, OCT 30 · 6 AM ET editionNext edition in Next --:--:--

Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness

Recruiting · PHASE 3 · AbbVie

What this means

Facial skin quality, including attributes such as skin smoothness, can be affected by intrinsic aging and environmental factors. The goal of this study is to evaluate the safety and effectiveness of NOA HYDRATION, an injectable gel designed for intradermal placement, in improving facial skin quality including attributes such as skin smoothness in Chinese adults.

A plain-English summary is on its way. Until then, this is the start of the registry's own summary.

Status
Recruiting
Who can join
Ages 18 and over
Where
4 sites

Contacts and how to join ↗

The science

Registered title
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
Phase
PHASE 3
Study type
interventional
Conditions
Skin Quality
What is tested
NOA HYDRATION
Sponsor
AbbVie
Ages
18 Years to no maximum
Dates
First posted Oct 19, 2026 · updated Oct 19, 2026

Registry summary

Facial skin quality, including attributes such as skin smoothness, can be affected by intrinsic aging and environmental factors. The goal of this study is to evaluate the safety and effectiveness of NOA HYDRATION, an injectable gel designed for intradermal placement, in improving facial skin quality including attributes such as skin smoothness in Chinese adults.

NOA HYDRATION is an investigational device being developed for improvement of facial skin quality including attributes such as skin smoothness. Participants are placed into one of two groups - a treatment group or a control group (no-treatment control). There is a 1 in 3 chance that participants will be assigned to the control group. Approximately 150 adult participants seeking improvement in skin quality including attributes such as skin smoothness will be enrolled at approximately 7 sites in China.

Participants in the treatment group will receive intradermal injections of NOA HYDRATION to the facial area (excluding forehead, nose, lips, and periocular areas) on Day 1. An optional touch-up treatment may be given at Day 31. The treatment group will be followed for 12 months after the last treatment. Participants in the control group will receive no treatment for 2 months, then may receive optional treatment and will be followed for 9 months after treatment.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a clinic. The effects of the treatment will be checked by medical assessments, questionnaires, photography, and checking for side effects.

Sites (4)

  • Beijing Hospital /ID# 281119, Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital (West) - Xidan Campus /ID# 280945, Beijing, Beijing Municipality, China
  • Nanjing Drum Tower Hospital /ID# 281047, Nanjing, Jiangsu, China
  • Zhejiang Provincial People's Hospital /ID# 281041, Hangzhou, Zhejiang, China
Report a problem